The AACR Annual Meeting covers the latest discoveries across the spectrum of cancer research – from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy – and highlights the work of the best minds in research and medicine from institutions all over the world.
When you plan your agenda, be sure to visit us at booth 2914 to learn how our comprehensive, integrated portfolio of services can support your oncology drug discovery and development programs from hit ID to IND. Utilizing the most effective combination of tools available to identify promising compounds, our broad range of models and support services allows clients to choose the most appropriate study design and screening method to identify promising compounds and optimize lead candidates. We have guided clients to success with a record of 61 patents and 17 clinical candidates and worked on 88% of oncology therapies approved in 2018. Our team can support your development of novel cancer therapeutics, every step of the way.
Charles River will also be presenting at the AACR Annual Meeting
We are honored to have the society select this work for an oral presentation. We hope that you will join as our scientists showcase this innovative and inspiring scientific content.
Monday, Apr 1, 3:00 - 5:00 p.m.
Modulation of the tumor infiltrating lymphocyte population by PARP inhibitor Talazoparib in combination with anti-PD1 treatment significantly enhances overall survival in a murine BRCA1-/- breast cancer model
Tuesday, Apr 2, 3:00 - 5:00 p.m.
Open science medicinal chemistry: Towards a treatment for DIPG
Scientific Poster Presentations:
Our scientists, in collaboration with our partners, are proudly presenting 19 scientific posters.
Sunday, March 31, 2019, 1:00 PM - 5:00 PM
- Patient-derived 3D tumor cultures for compound screening and pre-clinical drug development (Partnered with Ocello)
- PDX-derived 3D InSightTM tumor microtissues as ex-vivo human experimental models for evaluating therapeutic responses (Partnered with InSphero)
- All-in-one flow cytometry staining panel for immune-cell profiling in syngeneic tumor models (Partnered with ProQinase GmbH)
Monday, Apr 1, 8:00 a.m. - 12:00 noon
- Validation of humanized PD-1 knock-in mice as an emerging model to evaluate human specific PD-1 therapeutics
- A novel, monovalent tri-specific antibody-based molecule that simultaneously modulates PD-L1 and 4-1BB exhibits potent anti-tumoral activity in vivo (Partnered with Numab Therapeutics)
- PDX models of solid cancer express distinct cytokine profiles in humanized mice relating to their tumor infiltrating lymphocyte landscape
- Characterization of the immune checkpoint inhibitor response in the MC38 murine colon cancer model
- High content analysis of 2D and 3D oncology models for target and phenotypic drug discovery
- Validation of the interaction between a candidate compound and the intended drug target by a phenotypic rescue approach
- Bruteforcing immune oncology discovery with computational immuno-engineering (Partnered with Distributed Bio)
- Predictive models for tumor cell targeting with plinabulin, derived from in vitro screening and Affymetrix mRNA expression data (Partnered with BeyondSpring Pharmaceuticals)
Monday, Apr 1, 1:00 - 5:00 p.m.
- Translational imaging findings in a pediatric patient-derived orthotopic xenograft brain tumor model
- Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers (Partnered with 4HF Biotec GmbH)
Tuesday, Apr 2, 8:00 a.m. - 12:00 noon
- A translational immuno-oncology platform to model the tumor microenvironment in vitro
- Spatiotemporal changes in effector immunity in response to checkpoint blockade immune therapy in acute myeloid leukemia
- Broad spectrum activity of the BET inhibitor GSK 1324726A in hematologic and solid cancer cell lines in-vitro and determination of associated predictive biomarkers (Partnered with 4HF Biotec GmbH)
Wednesday, Apr 3, 8:00 a.m. - 12:00 noon
- Use of in vivo microdialysis to evaluate biomarker levels in the tumor and tumor free flank of freely-moving PDX mice
- Profile of ARX001822, a highly potent, selective and orally bioavailable A2a antagonist effective in preventing adenosinergic suppression of T cell activation (Partnered with AdoRx Therapeutics)
- Development of a vaccine model to track the CD8-specific response in large animals* (Partnered with Roche)
*Title has been changed due to its sensitive nature.